10x Genomics (NASDAQ: TXG) director sells under 10b5-1 plan
10x Genomics (NASDAQ: TXG) director Sarah A. Teichmann reported two open-market sales of Class A Common Stock, totaling 7,551 shares. These transactions, executed on August 13 and August 14, 2026, were conducted under a Rule 10b5-1 trading plan adopted on May 14, 2026. The sales amounted to approximately $432,000, leaving Teichmann with 28,058 shares of Class A Common Stock.
ARK Investment Management (TXG) reports 10.0M-share position in 10x Genomics
ARK Investment Management LLC and its CEO, Catherine D. Wood, have reported a beneficial ownership of 10,003,058 shares of 10x Genomics, Inc. Class A common stock as of June 30, 2026. This position represents an 8.56% stake in the company's outstanding Class A shares. The filing details the sole and shared voting and dispositive powers held by ARK and Wood over these shares.
10x Genomics Director John R. Stuelpnagel Sells 20,000 Shares in August 2026 SEC Filing
John R. Stuelpnagel, a Director at 10x Genomics, Inc. (NASDAQ:TXG), sold a total of 20,000 shares of Class A Common Stock on August 11, 2026. The sales were conducted in two open-market transactions, with 17,000 shares sold at a weighted average price of $57.5812 and 3,000 shares sold at $58.725. Following these transactions, Stuelpnagel's direct beneficial ownership in the company stands at 348,436 shares.
10x Genomics (TXG) director John Stuelpnagel sells 20,000 shares in August 11 trades
John R. Stuelpnagel, a director at 10x Genomics (TXG), sold a total of 20,000 Class A Common Stock shares on August 11, 2026. The sales were executed in two transactions: 17,000 shares at a weighted average price of $57.5812, and an additional 3,000 shares at $58.7250. This insider activity indicates a net sale of shares by a company director.
10x Genomics, Inc. SEC Filing (Aug 11, 2026)
This article reports on an SEC Form 144 filing by 10x Genomics, Inc. (TXG) dated August 11, 2026. The filing indicates a proposed sale of 20,000 shares of Class A common stock by a filer, with an aggregate market value of $1,155,032.36, through Wells Fargo Clearing Services on Nasdaq. The shares were originally granted as founder shares on August 21, 2017.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are expressing bullish sentiments on several healthcare stocks, specifically Elanco Animal Health (ELAN), Zimmer Biomet Holdings (ZBH), and 10x Genomics (TXG). Analysts from Piper Sandler and Canaccord Genuity have reiterated Buy ratings for these companies, setting price targets that suggest significant upside from current levels. The article highlights analyst consensus and individual analyst performance for each stock.
10x Genomics (TXG): Doubled, Then Doubled Again
10x Genomics (TXG) has been a significant winner for Hedgeye, with its stock price soaring over 157% since May 19 due to strong Signal Strength, favorable macroeconomic "Quads," and robust fundamental performance. The company recently reported strong second-quarter results, raised full-year guidance, and despite a tactical sale by CEO Keith McCullough for a 20% gain, it remains a "Best Idea Long" for Hedgeye's Health Care team. The success is attributed to the firm's comprehensive investment process, including academic grant cycle analysis for new lab technologies like spatial genomics, which is experiencing high demand.
Enterprise value to EBIT forward of 10x Genomics Inc Class A – BMV:TXG
This article provides financial information for 10x Genomics Inc Class A (BMV:TXG) on TradingView. It specifically highlights the company's enterprise value to EBIT forward metric. The content appears to be a stub or a placeholder page within a larger financial data platform.
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX)
Analysts have issued neutral "Hold" ratings for three healthcare companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG), and Teleflex (TFX). Bank of America Securities analysts Tazeen Ahmad, Michael Ryskin, and Travis Steed maintained Hold ratings for each respective company, citing various factors including stock performance relative to 52-week lows and updated price targets from other firms. While consensus for all three is a "Moderate Buy," price targets suggest varying upsides or downsides from current levels.
10x Genomics (NASDAQ: TXG) grows consumables, ends Q2 with $502M cash
10x Genomics reported a Q2 2026 total revenue of $151.0M, a 13% decrease from Q2 2025, primarily due to the absence of large, non-recurring patent-license settlements from the previous year. Despite this, underlying products and services revenue grew by 3% to $149.1M, driven by increases in consumables and services. The company ended the quarter with $502.5M in cash and cash equivalents and acquired Proteintech Genomics for $6.1M to expand its proteomics capabilities.
10x Genomics, Inc. (TXG) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of 10x Genomics, Inc. (TXG), including its current stock price, recent news, chart performance over various periods, and key financial data. The article details the company's products and services, such as the Chromium and Visium platforms and Xenium Analyzer, which are used for analyzing biological systems. It also presents analyst insights, earnings trends, and performance comparisons against benchmarks like the S&P 500.
10x Genomics, CHUV Expect Hundreds of Patients in Cancer Study
10x Genomics announced a multi-year research collaboration with Lausanne University Hospital (CHUV) to advance diagnostic applications of single cell and spatial technologies in cancer care. The study aims to identify clinically relevant biomarkers for predicting treatment response and prognosis across various solid tumors using 10x's Flex Apex and Xenium platforms, with plans to include hundreds of patients. This collaboration seeks to integrate single cell and spatial biology with clinical outcomes to improve personalized treatment strategies.
10x Genomics Inc Class A Revenue Breakdown – GETTEX:1KJ
This article details the revenue breakdown for 10x Genomics Inc Class A (GETTEX:1KJ). In the last fiscal year, the company generated 547.31 million EUR, with the Consumables - Single Cell segment contributing the most at 309.24 million EUR. The United States was the largest regional contributor, accounting for 295.03 million EUR of the revenue.
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
Shares of Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics all traded down after concerns arose over a rising number of uninsured patients, a trend highlighted in HCA Healthcare's recent earnings report. The "negative payer mix shift" could lead to more uncompensated care and squeeze profit margins for healthcare providers. Hims & Hers Health, despite its recent decline, has shown significant returns for long-term investors and recently partnered with Novo Nordisk for GLP-1 drug sales.
ETFs Investing in 10x Genomics Inc Class A Stocks
This article lists the various Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A (TXG) stocks. It provides a detailed table including fund names, market value of TXG holdings, weight in the fund, issuer, management style, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return for each ETF. The information helps investors identify funds offering exposure to 10x Genomics Inc.
TXG Stock Rallies As Wall Street Hikes Price Targets
10x Genomics Inc. (TXG) stock has rallied by 9.43% due to strong demand for its single-cell platform and increased price targets from Wall Street analysts. Barclays, Morgan Stanley, and Citi have all raised their price targets for TXG, indicating improved sentiment for life science tools and the company's strategic collaboration with Cleveland Clinic for advanced bladder cancer research. Despite a recent insider sale by CEO Serge Saxonov, the stock's momentum is driven by fundamental growth, positive cash flow, and bullish analyst calls.
TXG Stock Climbs As Wall Street Hikes Price Targets
10x Genomics Inc. (TXG) stock has surged over 12% following positive analyst coverage and strategic company developments. Barclays and Citi both raised their price targets for TXG, citing improving sentiment in life science tools and the potential for earnings growth. Key drivers include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic for advanced cancer research, despite a recent insider stock sale.
Price to sales forward of 10x Genomics Inc Class A – SWB:1KJ
This article provides the forward price-to-sales ratio for 10x Genomics Inc Class A (SWB:1KJ) listed on the Stuttgart Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content emphasizes financial data and market specifics for this biotechnology company.
ETFs Investing in 10x Genomics Inc Class A Stocks
This article lists various Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A stocks. It provides detailed financial information for each ETF, including market value, weight of the stock in the fund, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and NAV total return over three years. The ETFs are primarily focused on themes like innovation, genomics, small-cap, and health technology.
1KJ Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for 10x Genomics Inc Class A (1KJ) stock, based on analyst opinions. It includes details on price estimates, historical highs and lows, upcoming earnings reports, and financial metrics such as EPS, revenue, net income, and EBITDA. The content also addresses frequently asked questions about the company's stock.
10x Genomics, Cleveland Clinic study aims to predict bladder cancer treatment response
10x Genomics has announced a multi-year research collaboration with Cleveland Clinic to develop advanced diagnostic applications for bladder cancer. The study will utilize 10x Genomics' Flex Apex, Xenium, and later Atera platforms to analyze bladder cancer tumor samples. The primary goal is to identify biomarkers that can predict patient responses to antibody-drug conjugates and immunotherapies, ultimately aiding in personalized treatment decisions and future diagnostic development.
10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ)
This article provides an overview of 10x Genomics Inc Class A (FWB:1KJ) stock, including financial actuals and estimates, analyst forecasts, and company financial details. It covers stock price history, earnings, revenue, net income, lack of dividends, employee count, and EBITDA. The article also provides guidance on how to buy 1KJ stocks through online brokers.
1KJ Forecast — Price Target — Prediction for 2027
This article provides financial forecasts and key metrics for 10x Genomics Inc Class A (1KJ) listed on the Frankfurt Stock Exchange. It includes analyst price targets, historical highs and lows, upcoming earnings dates, and past financial performance like EPS, revenue, net income, and EBITDA. The content clarifies that it is not investment advice and encourages users to conduct their own research.
10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ)
This article provides financial actuals and estimates for 10x Genomics Inc Class A (1KJ) on the Dusseldorf Stock Exchange. It includes analyst opinions on future price targets, historical stock performance, earnings reports, revenue, net income, and employee information. The company does not pay dividends, and its next earnings report is expected on August 6, 2026.
Enterprise value to revenue forward of 10x Genomics Inc Class A – LSE:0A88
This article provides financial information for 10x Genomics Inc Class A (LSE:0A88), focusing on its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showcasing the company's financial metrics and data sources.
10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ)
This article provides financial actuals and estimates for 10x Genomics Inc Class A (MUN:1KJ), including income statement, balance sheet, and cash flow data. It covers analyst forecasts, historical price performance, upcoming earnings dates, recent earnings per share and revenue figures, net income, dividend policy, employee count, and EBITDA. The information is presented by TradingView and includes frequently asked questions about the stock.
10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG)
This article provides current and historical financial data and analyst estimates for 10x Genomics, Inc. (NASDAQ:TXG). It covers stock price performance, forecasts, market capitalization, earnings, revenue, and other key financial metrics. The company's next earnings report is anticipated on August 6, 2026, with recent earnings showing a significant surprise.
Price to sales forward of 10x Genomics Inc Class A – LSE:0A88
This article provides the "Price to sales forward" metric for 10x Genomics Inc Class A (LSE:0A88). It is a standalone financiero data point without additional analysis or context within the provided content. The relevant financial information is presented as "Period Value Change Change %" under the Price to Sales forward heading.
Price to earnings forward of 10x Genomics Inc Class A – LSE:0A88
This page from TradingView displays financial information for 10x Genomics Inc Class A (LSE:0A88), specifically focusing on its forward price-to-earnings ratio. The content indicates that while the company's stock is listed on the London Stock Exchange, the market was closed at the time of access, with no trades recorded. It serves as a financial data point within a larger platform offering market analysis and trading tools.
10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com
Serge Saxonov, CEO of 10x Genomics, sold 29,900 shares of company stock for over $1 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock was trading near its 52-week high after a significant gain. The company's stock is currently considered overvalued by InvestingPro analysis, despite recent strategic moves and partnerships.
10x genomics CEO Serge Saxonov sells $1.03m in stock
Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 29,900 shares of Class A Common Stock worth approximately $1.03 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock traded near its 52-week high, and Mr. Saxonov still holds significant direct and indirect shares. The company has also recently acquired Proteintech Genomics and entered a research collaboration with Cleveland Clinic, enhancing its technological capabilities.
10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan
10x Genomics (TXG) CEO Serge Saxonov sold 30,000 shares of Class A common stock on June 22, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales, totaling over $1 million, occurred at weighted average prices between $33 and $36 per share. After these transactions, Saxonov directly holds approximately 1.13 million shares, with additional indirect holdings through various trusts.
Form 4 10X Genomics Inc For: 24 June By Investing.com
This article reports on the filing of Form 4 by 10X Genomics Inc. for June 24, as published by Investing.com. It is a brief announcement without further details on the content of the Form 4 filing.
TXG - 10x Genomics Inc Stock Price and Quote
This article provides a detailed stock overview for 10x Genomics Inc (TXG), including its current stock price, financial metrics, analyst ratings, and recent news. It also lists insider transactions, highlighting sales by key executives. The company is involved in life science technology, building products to advance biology research.
10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades
10x Genomics, Inc. director Shehnaaz Suliman sold a total of 5,723 shares of Class A Common Stock in open-market transactions on June 16, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, at weighted average prices of $32.5890 and $33.2738 per share. Following these transactions, Suliman beneficially owns 32,086 shares of Class A Common Stock.
TXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary
TXG (10x Genomics, Inc.) has filed a Form 144 notice detailing proposed sales of Class A Common stock related to multiple RSU vesting events, with JP Morgan Securities LLC identified as an intermediary. The filing specifies various vesting dates between August 2021 and August 2024, alongside the respective share counts. This notice is routine for RSU-related proposed sales and does not disclose sale prices, proceeds, or completion status.
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
10x Genomics has acquired Proteintech Genomics, a division specializing in high-plex proteomic solutions for single cell and spatial applications on 10x platforms. This acquisition expands 10x Genomics' capabilities in proteomics and supports its vision for integrating transcriptomic and proteomic information in biological analysis. The deal is expected to accelerate innovation in multiomic approaches for research in immunology, oncology, neuroscience, and cell biology.
10x Genomics (TXG) awards 8,829 RSUs to company director
10x Genomics director Sarah A. Teichmann was awarded 8,829 restricted stock units (RSUs) of Class A Common Stock. These RSUs were granted at no cash cost and increased her direct holdings to 35,609 shares. The RSUs will vest in quarterly installments, with one-quarter vesting on each quarterly anniversary starting May 21, 2026, contingent on her continued service.
10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs
10x Genomics (TXG) director Kimberly J. Popovits was granted 8,829 Restricted Stock Units (RSUs) as an equity award, increasing her direct holdings to 37,445 shares. These RSUs will vest quarterly, starting May 21, 2026, contingent on her continued service. The grant is classified as an acquisition and not a market transaction, with a reported price of $0.0000 per share.
10x Genomics (TXG) awards 8,829 RSUs to board director
10x Genomics director, John R. Stuelpnagel, was granted 8,829 restricted stock units (RSUs). These RSUs will vest in four equal quarterly installments starting May 21, 2026, provided he remains a service provider. Following this grant, Stuelpnagel holds 368,436 shares of Class A Common Stock directly.
10x Genomics (TXG) director receives 8,829 RSUs vesting from 2026
10x Genomics director Alan Mateo has been granted 8,829 restricted stock units (RSUs) for Class A Common Stock. These RSUs will vest in four equal quarterly installments starting May 21, 2026, contingent upon his continued service. Following this grant, Mateo's direct holdings in the company's Class A Common Stock amount to 85,877 shares.
10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings
Sridhar Kosaraju, a director at 10x Genomics (TXG), was granted 8,829 Restricted Stock Units (RSUs) as part of a stock-based compensation award. This grant increases his direct holdings to 65,278 shares, with an additional 3,000 shares held indirectly through a family trust. The RSUs will vest in four equal quarterly installments beginning May 21, 2026, contingent on his continued service to the company.
10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman
10x Genomics director Shehnaaz Suliman has been granted 8,829 restricted stock units (RSUs) of Class A Common Stock, as reported in a recent Form 4 filing. This equity award, which has no cash purchase price, increases her direct holdings to 37,445 shares. The RSUs will vest in four equal quarterly installments beginning May 21, 2026, contingent on her continued service.
10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda
10x Genomics (NASDAQ: TXG) shareholders approved all proposals at their 2026 annual meeting, including the election of three Class I directors for three-year terms, the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, and the non-binding advisory approval of named executive officer compensation. A quorum was met with 90.5% of eligible votes represented. The final voting results for each proposal were detailed in the company's 8-K filing.
10x genomics CEO Serge Saxonov sells $709,057 in shares
Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales, conducted between $24.4415 and $24.7092 per share, included shares sold to cover tax obligations and those executed via a Rule 10b5-1 trading plan. The stock has seen a 197% gain over the past year but is considered overvalued by InvestingPro.
10x genomics CEO Serge Saxonov sells $709,057 in shares By Investing.com
Serge Saxonov, CEO of 10x Genomics, sold 28,893 shares of Class A Common Stock across two transactions last week, totaling approximately $709,057. These sales were related to tax obligations from restricted stock units and a pre-arranged trading plan. Despite his sales, Saxonov retains a significant holding in the company, which has seen a 197% gain over the past year but is considered overvalued by InvestingPro.
10x genomics president Hindson sells $283,399 in company stock By Investing.com
10x Genomics President and Chief Scientific Officer, Benjamin J. Hindson, sold 11,595 shares of company stock totaling $283,399 to cover tax obligations. This sale occurred while TXG stock was trading near its 52-week high after a significant 197% gain, though it appears overvalued based on current analysis. The company has recently seen an "Outperform" upgrade from William Blair and a raised price target from Stifel, despite concerns over potential AI model impacts and institutional investor reductions.
10x Genomics CFO Adam Taich sells $369,017 in stock By Investing.com
10x Genomics CFO Adam Taich sold 15,098 shares of the company's Class A Common Stock for $369,017 to cover tax withholding obligations. This transaction occurred as the shares trade near their 52-week high after a significant 197% gain over the past year. Adam Taich now directly holds 379,898 shares, while InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value.
10x genomics president Hindson sells $283,399 in company stock
Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (NASDAQ:TXG), sold 11,595 shares of company stock totaling $283,399 to cover tax obligations. This sale comes amidst various recent developments for 10x Genomics, including an "Outperform" rating from William Blair, collaboration with Bioptimus, and a raised price target from Stifel, despite concerns from a Microsoft AI model tweet and ARK Invest's share sale.
10x Genomics (TXG) CFO sells 15,098 shares to cover RSU taxes
10x Genomics CFO Adam Taich sold 15,098 shares of Class A Common Stock on May 22, 2026, at an average price of $24.4415 per share. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units and is considered a routine, compensation-driven sale. Following the sale, Taich still holds 379,898 shares of 10x Genomics Class A Common Stock.
